AU2003200914B2 - Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems - Google Patents

Description

AUSTRALIA

PATENTS ACT 1990 DIVISIONAL APPLICATION NAME OF APPLICANT: GTC Biotherapeutics, Inc.

ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Little Collins Street Melbourne, 3000.

INVENTION TITLE: "Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems" The following statement is a full description of this invention, including the best method of performing it known to us: NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING MRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS BACKGROUND OF THE INVENTION Field of the invention The invention relates to heterologous gene expression. More particularly, the invention relates to the expression of microbial or parasitic organism genes in higher eukaryote cell systems.

Summary of the related art Recombinant production of certain heterologous gene products is often difficult in in vitro cell culture systems or in vivo recombinant production systems.

For example, many researchers have found it difficult to express proteins derived from bacteria, parasites and virus in cell culture systems different from the cell from which the pr6tein was originally derived, and particularly in mammalian cell culture systems. One example of a therapeutically important protein which has been difficult to produce by mammalian cells is the malaria merozoite surface protein (MSP-1).

Malaria is a serious heath problem in tropical countries. Resistance to existing drugs is fast developing and a vaccine is urgently needed. Of the number of antigens that getexpressed during the life cycle of P. falciparum, MSP-I is the most extensively studied and promises to be the most successful candidate for vaccination.. Individuals exposed to P. fiilciparuim develop antibodies against MSP-1, and studies have shown that therg is a correlation between a naturally acquired immune response to MSP-1 and reduced malaria morbidity. In a number of studies, immunization with purified native MSP- or recombinant fragments of the protein has induced at least partial protection from the parasite (Diggs et al, (1993) Iaranlitl. Tt'iday 9:300-302). Thus MSP-1 is an important target for the 2 development of a vaccine against P. filciparwn.

MSP-1 is a 190-220 kDA glycoprotein. The C-terminal region has been the focus of recombinant production for use as a vaccine. However, a major problem in developing MSP-l as a vaccine is the difficulty in obtaining recombinant proteins in bacterial or yeast expression systems that are equivalent in immunological potency to the affinity purified native protein (Chang et al., (1992) i. Immnuol. 148:548-555.) and in large enough quantities to make vaccine production feasible.

Improved procedures for enhancing expression of sufficient quantities of proteins derived from parasite, bacterial and viral organisms which have previously been difficult to produce recombinantly would be advantageous. In particular, a recombinant system capable of expressing MSP-1 in sufficient quantities would be particularly advantageous.

BRIEF SUMMARY OF THE INVENTION The present invention provides improved recombinant DNA compositions and procedures for increasing the mRNA levels and protein expression of proteins derived from heterologous cells, preferably those of lower organisms such as bacteria, virus, and parasite, which have previously been difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic mammals. The preferred protein candidates for expression in an expression system in accordance with the invention are those proteins having DNA coding sequences comprising high overall AT content or AT rich regions, and/or mRNA instability motifs and/or rare codons relative to the ree~mbinant expression systems.

In a first aspect, the invention features a modified known nucleic acid, preferably a gene from a bacterium, virus or parasite, capable of being expressed in a system, wherein the modification comprises a reduced AT content, relative to the unmodified sequence, and optionally further comprises elimination of at least one or all mRNA instability motifs present in the natural gene. In certain preferred embodiments the modification further comprises replacement of one or more codons of the natural gene with preferred codons of the cell system.

I[na second aspect, the invention provides a process for preparing a modified nucleic acid of the invention comprising the steps of lowering the overall AT content of the natural gene encoding the protein, and/or eliminating at least one or all mRNA instability motifs and/or replacing one or more codons with a preferred.

codon of the cell system of choice, all by replacing one or more codons in the.natural gene with codons recognizable to, and preferably with codons preferred by the cell system of choice and which code for the same amino acids as the replaced codon.

This aspect of the invention further includes modified nucleic acids prepared according to the process of the invention.

In a third aspect, the. invention also provides vectors comprising nucleic acids of the invention and promoters active in the cell line or organism of choice, and host cells transformed with nucleic acids of the invention.

In a fourth aspect, he invention provides transgenic expression vectors for the production of transgenic lactating animals comprising nucleic acids of the invention as well as transgenic non-human lactating animals whose germlines comprise a nucleic acid of the invention.

In a fifth aspect, he invention provides a transgenic expression vector for production of a transgenic lactating animal species comprising a nucleic acid of the invention, a promoter operatively coupled to the nucleic acid which directs mammary gland expression of the protein encoded by the nucleic acid into the milk of the transgenic animal.

In a sixth aspect, the invention provides a DNA vaccine comprising a modified nucleic acid according.to the invention. A preferred embodiment of this aspect of the invention comprises a fragment of a modified MSP-1 gene according to the invention.

DESCRIPTION OF THE DRAWINGS Fig. 1 depicts the cDNA sequence of MSP-14: modified in accordance with the invention (SEQ ID NO 1] in which 306 nucleotide positions have been replaced to lower AT content and eliminate mRNA instability motifs while maintaining the same protein amino acid sequence of MSP-1 42 The large letters indicate nucleotide substitutions.

Fig. 2 depicts the nucleotide sequence coding sequence of the "wild type" or native MSP- 142 (SEQ ID NO 2].

Fig 3a is a codon usage table for wild type MSP-1 4 2 (designated "MSP wt" in the table) and the new modified MSP-1 4 2 gene (designated "edited MSP" in the table) and several milk protein genes (casein genes derived from goats and mouse). The numbers in each column indicate the actual number of times a specific codon appears in each of the listed genes. The new MSP-1 4 2 synthetic gene was derived from the mammary specific codon usage by first choosing GC rich codons:for a given amino acid combined with selecting the amino acids used most frequently in the milk proteins.

Fig 3b is a codon usage table comparing the number of times each codon appears in both the wild type MSP-1 42 (designated "MSP wt" in the table) and the new modified MSP-1 42 .gene (designated "edited MSP" in the table) as is also shown in the table in Fig. 3a. The table in Fig. 3b, also compares the frequency in which each codon appears in the wild type MSP-1 4 and the new modified MSP-142 gene, to the frequency of appearance of each codon in both E.coli genes and human genes. Thus, if the expression system were E.coli cells, this table may be used to determine what codons are recognized by, or preferred by E-oli.

Fig. 4a-c depict NMSP-142 constructs GTC 479, GTC 564, and GTC 627, respectively as are described in the examples.

Fig. 5 panel A is a Northern analysis wherein construct GTC627 comprises the new MSP-1 42 gene modified in accordance with the invention, GTC479 is the construct comprising the native MSP-1 4 2 gene, and construct GTC469 is a negative control

DNA

Fig 5 panel B is a Western analysis wherein the eluted fractions after affinity purifications. Numbers are collected fractions. The results show that fractions from GTC679 the modified MSP-1 42 synthetic gene construct reacted with polyclonal antibodies to MSP-1 and the negative control GTC479 did not..

Fig 6 depicts the nucleic acid sequences of OT1 [SEQ ID NO 31, OT2 [SEQ ID NO 4), MSP-S [SEQ ID NO 5] MSP-2 [SEQ ID NO 61 and MSP1 [SEQ ID NO 7] described in the Examples.

Fig 7 is a schematic representation of plasmid BC574.

Fig 8 is a schematic representation of BC620.

Fig 9 is a schematic representation of BC670.

Fig 10 is a representation of a Western blot of MSP in transgenic milk.

Fig 11 is a schematic representation of the nucleotide sequence of MSP42-2 [SEQ ID NO 8].

Fig 12 is a schematic representation of the BC-718.

Fig 13 is a representation of a Western blot of BC-71S expression in transgenic milk.

7-.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued US patents, allowed applications, published foreign applications, and references cited herein are hereby incorporated by reference. Any conflicts between these references and the present disclosure shall be resolved in favor of the present disclosure.

The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of proteins which are known to be, or are likely to be, difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals.

The preferred "difficult" protein candidates for expression using the recombinant techniques of the invention are those proteins derived from heterologous cells preferably those of lower organisms such as parasites, bacteria, and virus, having DNA coding sequences comprising high overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the recombinant expression system to be used.

In a first aspect, the invention features a modified known nucleic acid, preferably a gene from a bacterium, virus or parasite, capable of being expressed in a cell system, wherein the modification comprises a reduced AT content, relative to the unmodified sequence, and optionally further comprises elimination of at least one or all mRNA instability motifs present.in the natural gene. A '"cell system" includes cell culture systems, tissue culture systems. organ culture systems and tissues of living animals. In certain preferred embodiments the modification further comprises replacement of one or more codons of the natural gene with preferred codons of the cell system. Each of these features are achieved by replacing one or more codons of the natural gene with codons recognizable to, and preferably preferred by the cell system that encode the same amino acid as the codon which was replaced in the natural gene. In accordance with the invention, such "silent" nucleotide and codon substitutions should be sufficient to achieve the goal lowering AT content and/or of eliminating mRNA instability motifs, and/or reducing the number of rare codons, while maintaining, and preferably improving the ability .of the cell system to produce mRNA and express the desired protein.

Also included in the invention are those sequences which are specifically homologous to the modified nucleic acids of the invention under suitable stringent conditions, specifically excluding the known nucleic acids from which the modified nucleic acids are derived. A sequence is "specifically homologous" to another sequence if it is sufficiently homologous to specifically hybridize to the exact complement of the sequence. A sequence "specifically hybridizes" to another sequence if it hybridizes to form Watson-Crick or Hoogsteen base pairs either in the body, or under conditions which approximate physiological conditions with respect to ionic strength, 140 mM NaCI, 5 mM MgClI. Preferably, such specific hybridization is maintained under stringent conditions, 0.2X SSC at.68*C.

In preferred embodiments, .the nucleic acid of the invention is capable of expressing the protein in mammalian cell culture, or in a transgenic animal at a level which is at least 25%, and preferably 50%, and even more preferably at least 100% or more of that expressed by the natural gene in an in vitro cell culture system or in a transgenic animal under identical conditions the same cell type, same culture conditions, same expression vector).

As used herein, the term "expression"-is meant mRNA transcription resulting in protein expression.. Expression may be measured by a number of techniques known in the art including using an antibody specific for the protein of interest. By "natural gene" or "native gene" is meant the gene sequence, or fragments thereof (including naturally occurring allelic variations), which encode the wild type form of the protein and from. which the modified nucleic acid is derived. A "preferred codon "means a codon which is used more prevalently by the cell system of choice. Not all codon changes described herein are changes to a preferred codon, so long as the codon replacement is a codon which is at least recognized by the cell system. The term "reduced AT content" as used herein means having a lower overall percentage of nucleotides having A (adenine) or T (thymine) bases relative to the natural gene due to. replacement of the A or T containing nucleotide positions or A aid/or T containing codons with nucleotides or codons recognized by the cell system of choice and which do not change the amino acid sequence of the target protein. "Heterologous" is used herein to denote genetic material originating from a different species than that into which it has been introduced, or a protein produced from such genetic material.

Particularly preferred cell systems of the invention include mammalian cell culture systems such as COS cells and CHO cells, as well as transgenic animals, particularly the mammary tissue of transgenic animals. However, the invention also contemplates bacteria, yeast, E. coli, and viral expression systems such as baculovirus and even plant systems.

In a second aspect, the invention provides a process for preparing a modified nucleic acid of the invention comprising the steps of lowering the overall AT content of the natural gene encoding the protein, and/or eliminating at least one or all mRNA instability motifs and/or replacing one or more codons with a preferred codon of the cell system of choice, all by replacing one or more codons in the natural gene with codons recognizable to, and peferably with codons preferred by the cell system of choice and which code for the same amino acids as the replaced codon.

Standard reference works describing the general principals of recombinant DNA.

technology include Watson, J.D. et al, Molecular Biology of the Gene, Volumes I and IIthe Benjamin/Cummings Publishing Company,.Inc. publisher, Menlo Park, CA (1987).Darnell, J.E. etal., Molecular Cell Biology. Scientific American Books, Inc., Publisher, New York, NY (1986); Old, et al., Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2d edition, University of California Press, publisher, Berkeley CA (1981); Maniatis, et al., Molecular Cloning: A Laboratory.

Manual. 2 nd ed. Cold Spring Harbor Laboratory, publisher, Cold Spring Harbor. NY (19S9) and Current Protocols in Molecular Biology. Ausubel et al., Wiley Press. New York, NY (1992). This aspect of the invention further includes modified.nucleic acids prepared according to the process of the invention.

Without being limited to any theory, previous research has indicated that a conserved AU sequence (AUUUA) from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation (Shaw, G. and Kamen, R. Cell 46:659-667). The focus in the past has been on the presence of these instability motifs in the untranslated region of a gene. The instant invention is the first to recognize an advantage to eliminating the instability sequences in the coding region of a gene.

In a third aspect, the invention also provides vectors comprising nucleic acids of the.invention and promoters active in the cell line or organism of choice, and host cells transformed with nucleic acids of the invention. Preferred vectors include an origin of replication and are thus replicatable in one or more cell type. Certain .preferred-vectors are expression vectors, and further comprise at least a promoter and passive terminator, thereby allowing transcription of the recombinant expression element in a bacterial, fungal, plant, insect or mammalian cell.

In a fourth aspect, he invention provides transgenic expression vectors for the production of transgenic lactating animals comprising nucleic acids of the invention as well as transgenic non-human lactating animals whose germlines comprise a nucleic acid of the invention. Such transgenic expression vectors comprise a promoter capable of being expressed as part of the genome of the host transgenic animal. General principals for producing transgenic animals are known in the art. See for example Hogan et alt, Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor laboratory, (1986); Simons et al, Bio/Teclitology 6:179-183, (1988); Wall et al., Biol. Repirod. 32:645-631, (1985); Buhler et al., Bio/Techlology, 8:140-143 (1990); Ebert et al., Bio/Technolog!i 9:835-83S (1991); Krimenfort et al., Bio/Teclhnoloy 9:844-847 (1991): Wall et al., ].Cell. Biochem.

49:113-120 (1992).. Techniques for introducing foreign DNA sequences into mammals and their germ cells were originally developed in the mouse. See e.g., Gordon et al., Proc. Natl. Acad. Sci. USA 77:7380-7384. (1980); Gordon and Ruddle, Science 214: 1244-1246 (1981); Palmiter and Brinster, Cell 41: 343-345, 1985; Brinster et al., Proc Natl. Acad Sci., USA 82:4438-4442 (1985) and Hogan et al. (ibid.). These techniques were subsequently adapted for use with larger animals.including cows and goats. Up until very recently, the most widely used procedure for the generation of transgenic mice or livestock, several hundred linear molecules of the DNA of interest in the form of a transgenic expression construct are injected into one of the pro- nuclei of a fertilized egg. Injection of DNA into the cytoplasm of a zygote is also widely used. Most recently cloning of an entire transgenic cell line capable of injection into an unfertilized egg has been achieved (KHS Campbell et al., Nature 380 64-66, .(1996)).

In a fifth aspect, he invention provides a transgenic expression vector for production of a transgenic lactating animal species comprising a nucleic acid of the invention, a promoter operatively coupled to the nucleic acid which directs mammary gland expression of the protein encoded by the nucleic acid into the milk of the transgenic animal. The mammary gland expression system has the advantages of high expression levels, low cost, correct processing and accessibility.

Known proteins, such as bovine and human alpha- lactalbumin have been produced in lactating transgenic animals by several researchers. (Wright et al, Bio/Technology 9:830-834 (1991); Vilotte et al, Eur. 1. Biochemi.,186:43-48 (1989); Hochi et al., Mol Reprod. And DCvel. 33:160-164 (1992); Soulier et al.. FEBS Letters 297(1,2):13-18 (1992)) and the system has been shown to produce high levels of protein.

Preferred promoters are active in the mammary tissue. Particularly useful are promoters that are specifically active in genes encoding milk specific proteins such as genes found in mammary tissue, i.e. are more active in mammary tissue than in other tissues under physiological conditions where milk is synthesized. Most preferred are promoters that are both specific to and efficient in mammary tissue.

Among such promoters, the casein, lactalbumin and lactalglobulin promoters are preferred, including, but not limited to the alpha, beta and gamma casein promoters and the alpha lactalbumin and beta-lactalglobulin promoters. Preferred among the promoters are those from rodent, goats and cows. Other promoters include those that regulate a whey acidic protein (WAP) gene.

In a preferred embodiment of the invention, a modified nucleic acid encoding MSP-1 or fragments thereof capable of expression in a cell culture system, mammalian cell culture system or in the milk of a transgenic animal' is provided.

Nucleic acid sequences encoding the natural MSP-1 gene are modified in accordance with the invention. First the overall AT content is reduced by replacing codons of the natural gene with codons recognizable to, and preferably with codons preferred by the cell system of choice, that encode the same amino acid but are sufficient to lower the AT content of the modified nucleic acid as compared to the native MSP-1 gene or gene fragment. Second, mRNA instability motifs (AUUUA, Shaw and Kamen, supra) in the native gene or gene fragment are eliminated from the coding sequence of the gene by replacing codons of the natural gene with codons recognizable to, and preferably prefrred by the cell system of choice that encode the same amino acid but are sufficient to eliminate the mRNA instability motif.

Optionally, any other codon of the native gene may be replaced with a preferred codon of the expression system of choice as described.

In a sixth aspect, the invention provides a DNA vaccine comprising a modified nucleic acid according to the invention. In certain preferred embodiments, the DNA vaccine conprisei'a vector according to the invention, The DNA vaccine according to the invention may be in the form of a "naked" or purified modified nucleic acid according to the invention, which may or may not be operatively associated with a promoter. A nucleic acid is operatively associated with a promoter if it is associated with the promoter in a manner which allows the nucleic acid sequence to be expressed. Such DNA vaccines may be delivered without encapsulation, or they may be delivered as part of a liposome, or as part of a viral genome. Generally, such vaccines are delivered in an amount sufficient to allow expression of the nucleic acid and elicit an antibody response in an animal, including a human, which receives the DNA vaccine. Subsequent deliveries, at least one week after the first delivery, may be used to enhance the antibody response. Preferred delivery routes include introduction via mucosal membranes, as well as parenteral administration.

A preferred embodiment of this aspect of the invention comprises a fragment of a modified MSP-1 gene according to the invention. Such fragment preferably includes from about 5% to about 100% of the overall gene sequence and comprises one or more modification according to the invention.

Examples of codon usage from E.coli and human are shown in Fig. 3b. Fig. 3b shows the frequency of codon usage for the MSP-1 native gene as well as the modified MSP-1 gene of the invention and also compares the frequency of codon usage to that of E. coli and human genes. Codon usage frequency tables are readily available and known to those skilled in the art for a number of other expression systems such as yeast, baculovirus and the mammalian, systems.

The following examples illustrate certain preferred modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results.

Examples Creation of novel modiified MSP-T. 4gene In one embodiment, a novel modified nucleic acid encoding the C-terminal fragment of MSP-1 is provided. The novel, modified nucleic acid of the invention encoding a 42 kD C-terminal part of MSP-1 (MSP-1 4 2 capable of expression in mammalian cells of the invention is shown in Fig. 1. The natural MSP-1 4 2 gene (Fig 2) was not capable of being expressed in mammalian cell culture or in transgenic mice Analysis of the natural MSP- 142 gene suggested several characteristics that distinguish it from mammalian genes. First, it has a very high overall AT content of 76%. Second, the mRNA instability motif. AUUUA, occurred times in this 1100 bp DNA segment (Fig To address these differences a new MSP-1 42 gene was designed. Silent nucleotide substitution was introduced into the native MSP-14 2 gene at 306 positions to reduce the overall AT content to 49.7%. Each of the 10 AUUUA mRNA instability motifs in the natural gene were eliminated by changes in codon usage as well. To ctange the codon usage, a mammary tissue specific codon usage table, Fig. 3a. was created by using several mouse and goat mammary specific proteins. The table was used to guide the choice of codon usage for the modified MSP-1 42 gene as described above. For example as shown in the Table in Fig. 3a, in the natural gene, 65% (25/38) of the Leu was encoded by TTA, a rare codon in the mammary gland. In the modified MSP-1 42 gene, 100% of the Leu was encoded by CTG, a preferred codon for Leu in the mammary gland.

An expression vector was created using the modified MSP-1 42 gene by fusing the first 26 amino acids of goat beta-casein to the N-terminal of the modified MSP-1 42 gene and a Sall-Xho I fragment which carries the fusion gene was subcloned into the XhoI site of the expression vector pCDNA3. A His6 tag was fused to the 3' end of the MSP-1 42 gene to allow the gene product to be affinity purified. This resulted in plasmid GTC627 (Fig.4c).

To compare the natural MSP-1 42 gene construct to the modified MSP-1 42 nucleic acid of the invention, an expression vector was also created for the natural MSP-1 42 gene and the gene was added to mammalian cell culture and injected into mice to form transgenic mice as follows: Construiction of the nutive MSP-14, Expression Vector To secrete the truncated the merozoite surface protein-I (MSP-1) of Plasmodium falciparum, the wild type gene encoding the 42KD C-terminal part of MSP-1 (MSP-1 4 2) was fused to either the DNA sequence that encodes the first 15 or the first amino acids of the goat beta-casein. This is achieved by first PCR amplify the MSP-1 plasmid (received from Dr. David Kaslow, NIH) with primers MSP1.and MSP2 (Fig. then cloned the PCR product into the TA vector (Invitrogen). The Bgl[I-Xhol fragments of the PCR procLuct was ligated with oligos OT1 and OT2 (Fig.

6) into the expression vector pCDNA3. This yielded plasmid GTC564 (Fig.4b) which encodes the 15 amino acid beta- casein signal peptide and the first 11 amino acids of the mature goat beta-casein followed by the native MSP-1 42 gene. Oligos MSP-S and MSP-2 (Fig. 6) were used to amplify MSP-1 plasmid by PCR, the product was then cloned into TA vector. The Xhol fragment was exercised and cloned into the XhoI site of the expression vector pCDNA3 to yield plasmid GTC479 (Fig.4a), which encoded 15 amino acid goat beta-casein signal. peptide fused to the wild-type MSP-1 42 gene. A Hisb6 tag was added to the 3' end of MSP-1 42 gene in GTC 564 and GTC 479.

Nntive MSP-1 42 Gene Is Not Expressed In COS-7 Cells Expression of the native MSP gene in cultured COS-7 cells was assayed by- transient transfection assays. GTC479 and GTC564 plasmids DNA were introduced into COS-7 cells by lipofectamine (Gibco-BRL) according to manufacturer's protocols. Total cellular RNA was isolated from the COS cells two days post-transfection. The newly synthesized proteins were metabolically labeled for 10 hours 15V adding methionine added to the culture media two days-post transfection.

To determine the MSP mRNA expression in the COS cells, a Northern blot was probed with a 32P labeled DNA fragment from GTC479. No MSP RNA was detected in GTC479 or GTC564 transfectants (data not shown). Prolonged exposure revealed residual levels of degraded MSP mRNA. The 3SS labeled culture supernatants and the Ivsates were immunoprecipitated with a polyclonal antibody raised against MSP.

Immunoprecipitation experiments showed that no expression from either the lysates or the supernatants of the GTC479 or GTC564 transfected cells (data not shown). These results showed that the native MSP-1 gene was not expressed in COS cells.

Native MSP-1 4 2 Gene is Not Expressed in the Maumnary Gland of Transgenic Mice The SalI-XhoI fragment of GTC479, which encoded the 15 amino acids of goat betacasein signal peptide, the first 11 amino acids of goat beta-casein, and the native MSP-1 42 gene, was cloned into the Xhol site of the beta-casein expressed ir vector BC350. This yielded plasmid BC574 (Fig.7). A Sall-Not fragment of BC574 was injected into the mouse embryo to generate transgenic mice. Fifteen lines of transgenic mice were established. Milk from. the female founder mice was collected and subjected to Western analysis with polycolonal antibodies against MSP. None of the seven mice analyzed were found to express MSP-1 42 protein in their milk. To.

further determine if the mRNA of MSP-1 4 2 was expressed in the mammary gland, total RNA was extracted from day 11 lactating transgenic mice and analyzed by Northern blotting. No MSP-1 42 mRNA was detected by any of the BC 574 lines analyzed. Therefore, the MSP-1 4 2 transgene was not expressed in the mammary gland of transgenic mice. Taken together, these experiments suggest that native parasitic MSP-142 gene could not be expressed in mammalian cells, and the block is as the level of mRNA .abundance.

Exj~rssi '.Of 4S P ill the ManinrLian Cells Transient transfection experiments were performed to evaluate the expression of the modified MSP-1 42 gene'Of the invention in COS cells. 'GTC627 and GTC479 DNA were introduced into the COS-7 cells. Total RNA was isolated 48 hours post-transfection for Northern analysis. The immobilized RNA was probed with 32p labeled SalI-Xhol fragment of GTC627. A dramatic'cdifference was observed between GTC479 and GTC627. While no MSP-1 4 2 mRNA was detected in the GTC479 transfected cells .as shown previously, abundant MSP-1 42 mRNA was expressed by GTC627 (Fig. 5, Panel A) 4 TC 469 was used as a negative control and comprises the insert of GTC564 cloned into cloning vector PU19, a commercially available cloning vector. A metabolic labeling experiment with 315 methionine followed by immunoprecipitation with polvclonal *antibody (provided by, b. Kaslow NIAID, NIH) against MSP showed that MSP-1 42 protein was synthesized by the transfected COS cells (Fig.5, Panel B.Furthermore, M'%SP-1 4 2 was detected in the transfected- COS supernatant, Iindicating the MSP-1 42 protein was also secreted.

Additionally, using Ni -NTA column, MVSP-1 42 was affinity purified from the GTC627 transfected COS supernatant.

These results demonstrated that the modification of the parasitic SP1 2 gene lead to the expression of MSP mRNA in'the COS cells. Consequently" the MSP-1 42 product was synthesized and secreted by mamnmalian cells.

Polyclonal antibodies. used in this experiment may also be prepared by means well known in the art (Antibodies: A Lnborlitory MIu~l, Ed H-arlow and David Lane, eds. Cold Spring Harbor Laboratory,.publishers (1988)). Production of NISP serum antibodies is also described in Chang etal., Infiectivii andl 11.11)11LlitII1 (1996) 64:253-261 and Chang et al.. (1992) Proc Natl. Aceuul.. Sci. LISA 86:6343-6347.

The results of this analysis indicate that the modified MSP-14 nucleic acid of the invention is expressed at a \;ery high level compared to that of the natural protein which was not expressed at all. These. results represent the first experimental evidence that reducing the AT in a gene leads to expression of the MSP gene in heterologous systems and also the first evidence that removal of AUUUA mRNA instability motifs from the MSP coding region leads to the expression of MSP protein in COS cells.

Thus, the data presented here suggest that certain heterologous proteins that may be difficult to express in cell culture or transgenic systems because of high AT content and/or the presence of instability motifs, and or the usage of rare codons which are unrecognizable to the cell system of choice may be reengineered to enable expression in any given system with the aid of codon usage tables for that system. The present invention represents the first time that a DNA sequence has been modified with the goal of removing suspected sequences responsible for degradation resulting in low RNA levels or no RNA at all. The results shown in the Fig. 5, Panel A Northern no RNA with native gene and reasonable levels with a modified DNA sequence in accordance with the invention), likely explains the increase in protein production.

The following examples describe the expression of MSP1-42 as a native non-fusion (and non-glycosylated) protein in the milk of transgenic mice.

Constructirin of MSP Transgene To lusc MSPI-42 to the 15 amino acid L.-ascin signal pcptide. a pair ol oligos. MSP203 and MSP204 (MSP203: ggCcgcclgacLccaccalgaauggccLcataattgcc lgtcggtggctctggcattgcayccgtcactccclccglcae. MSP204: cgatgacggaggagtgcgcita caal aeagccaLcagacamgaatautgagace.'ttctt tia). which encode th: 15 anino ucid cascin signal and the*I irst 5 amino acid of the MSP I-42 ending, at the Cla 1 site. was Iligated with a Cla I-Xho I fragment ol BC62() (Fig. 8) which encodes the rest of the MSP 1-42 g'ene. into the Xho I site of the expression vector pCDNA3. A Xho I1 fragment (if this plasmid (GTC669) was Lhen cloneCd into, the Xho I site of milk specific expression vector BC350) to generate B670 (Fig.9) Exrpresski of MSP 1 -42 in thi milk oftrawsgcwiiice ASal f-ot I fragment w as prepared from plasrnid BC670) and microin etd into the mousceb)tigeeae tan ei ie Transgenic mice was identified by extracting. mouNe DNAfrom tail biopsy folowcd by PCR analysis using olgos GTC17 and MSP10I (sequences .ot (iligo~s: GTC 17. GA1TGACAAGTAATACGCTGTITCCTC. Oligo MSP 101, GGATTCAATAGATACGG). Milk'from thc female founder transizeni mice was collected at day 7 and day 9 of lactation. and subjct~ed to w~ktem analysis to determine the c.xpression leve (if MSP-l1-42 using an polyclonal anti-MSP ntihodv and monoclonal anti MSP-anibody 5.2 (Dr..

David Kaslowv. NIH). Results indicated that the level of MSP- i -42 expression in the milk ot transgenic mice was at 1-2 mg/mI (Fig;* C01IS11ruclion of 'MSP 1-4? qic'4vcoSvI~lriotI Sites mnu1s miu1ttunts1.

Our analysis of the milk produced MSP revealed that the transgenic'NISP protein was N- lycosylated. To eliminate the N-glycosylation sites intdie MSP 1-42 gene. Asn. at positions 18 1 and 262 were substituted with GIln.(Q). The Substitutions were introduced by designing DNA oligos that anneal to the corresponding region of MSP I and carry the AAC to CAG mutations. These uligos were then used as'PCR primers to produce DNA fragments that encode the N ito Q substitutions.

To introduce N262-Q mutation, a pair of oligos, MSPGYLYCO-3.

(CAGGOAATOCTGCAGATCAGC) AND MSP42-2 (AATrCTCGAGTTAGTG GTGGTGGTGGTGGTGATCGCAGAAAATACCATG. FIG. 11). were used to PCR amplity.

plasmid GTC627, which contains the synthetie MSPI-42 gene. The PCR product was cloned into pCR2.1 vector (Invitrogen). This generated plasmid GTCJ 16.

AACTTGTAGGG) and MSPGLCO-2 (GTCCTGCAGTACACATATGAG. Fig 41) were used to P:'OPERjms\ 108799.pagc20 doc.-003,03 amplify plasmid GTC 627. The PCR product was cloned into pCR2.1. This generated plasmid GTC700.

The MSP double glycosylation mutant was constructed by the following three steps: first, a Xho I-Bsm I fragment of BC670 and the Bsm I-Xho I fragment of GTC716 is ligated into the Xho I site of vector pCR2.1. This resulted in a plasmid that contain the MSP-1-42 gene with N262-Q mutation. EcoN I-Ndc I fragment of this plasmid was then replaced by the EcoN I-Ndc I fragment from plasmid GTC716 to introduce the second mutation, N181-Q. A Xho I fragment of this plasmid was finally cloned into BC350 to generate BC718 (Fig. 12).

Expression ofnonglycosylated MSP1 in transgenic animals BC718 has the following characteristics: it carries the MSP1-42 gene under the control of the P-casein promoter so it can be expressed in the mammary gland of the transgenic animal during lactation. Further, it encodes a 15 amino acid 0-casein leader sequence fused directly to MSP1-42 so that the MSP1-42, without any additional amino acid at its N-terminal, can be secreted into the milk. Finally, because the N-Q substitutions, the MSP produced in the milk of the transgenic animal'by this construct will not be N-glycosylated. Taken together, the transgenic MSP produced int the milk by BC718 is the same as the parasitic MSP.

A SaII/XhoI fragment was prepared from plasmid BC718 and microinjected into mouse embryos to generate transgenic mice. Transgenic animals were identified as described previously.

Milk from female founders was collected and analyzed by Western blotting with antibody 5.2. The results, shown in Figure 13, indicate expression of nonglycoslated MSP1 at a concentration of to 1 mg/ml.

Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents are considered to be within the scope of the invention, and are covered by the following claims.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

Claims (10)

17-01-'07 12:06 FROM- T-283 P004/23 F-047 SIDPEtRHPWlZTC Bahfrqpetli I \Ic4 ClaisrI AcceptWL DOCIh1701/2n O O -21- STHE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: r-- 1. A modified nucleic acid sequence encoding a parasite protein or fragment thereof, wherein the naturally occurring nucleic acid sequence encoding said parasite protein or fragment thereof contains at least one AUUUA mRNA instability motif, Sand wherein said nucleic acid sequence encoding said parasite protein or fragment 0 thereof has been modified by: S(a) replacing at least a portion of an AUUUA mRNA instability motif in the Scoding sequence of said parasite protein or fragment thereof as it naturally occurs in a parasite with a codon or codons preferred by a mammalian cell for the purposes of expression so as to remove said AUUUA mRNA instability motif or prevent said AUUUA mRNA instability motif from destabilising mRNAs encoding said parasite protein or fragment thereof while encoding the same amino acid as the replaced portion of said AUUUA mRNA instability motif; and replacing one or more AT-containing codons of said nucleic acid sequence as it naturally occurs in a parasite with a codon or codons preferred by a mammalian cell for the purposes of expression and encoding the same amino acid as the replaced codon, wherein the AT content of the modified nucleic acid sequence is 50% or less and/or all said AUUUA mRNA instability motifs are eliminated, wherein at least one glycosylation site on the parasite protein or fragment thereof has been altered. 2. The modified nucleic acid sequence of claim 1 encoding a parasite protein or fragment thereof, wherein the at least one glycosylation site is at least one N- glycosylation site. 3. The modified nucleic acid sequence of any one of claims 1 or 2, wherein all of the glycosylation sites have been altered. COMS ID No: SBMI-05951604 Received by IP Australia: Time 12:10 Date 2007-01-17 17-01-'07 12:07 FROM- T-283 P05/23 F-047 (*Roiwt\GPTCiallpit n Ui*uClairu luaAcuPainDDC-I O 09m1T S- 22- 4. The modified nucleic acid sequence of claim 1, wherein the parasite protein is a malarial protein. The modified nucleic acid sequence of any one of claims 1 to 4, wherein the or each codon preferred by a mammalian cell for the purposes of expression is a o mammary tissue specific codon. 6. The modified nucleic acid sequence of claim 1, wherein said modified nucleic Sacid sequence is capable of expressing said parasite protein or fragment thereof at a level which is at least 100% of that expressed by the nucleic acid sequence as it naturally occurs in a parasite in an in vitro or in vivo mammalian cell system under identical conditions. 7. A modified nucleic acid sequence of any one of claims 1 to 6, wherein said parasite is malaria and said nucleic acid sequence is a fragment of SEQ ID NO: 1 or a sequence specifically homologous thereto. 8. A vector comprising a modified nucleic acid sequence of any one of claims I to 7. 9. A mammalian cell transfected or transformed with the vector of claim 8. A transgenic expression construct comprising a modified nucleic acid sequence of any one of claims 1 to 7, 11. A transgenic expression construct for the production of a non-human transgenic mammal, comprising a modified nucleic acid sequence of any one of claims 1 to 7, operatively linked to a promoter which directs expression of the parasite protein or fragment thereof encoded by said modified nucleic acid sequence in the milk of said mammal. COMS ID No: SBMI-05951604 Received by IP Australia: Time 12:10 Date 2007-01-17 17-01-'07 12:07 FROM- T-283 P006/0a23 F-047 P1 OPglftMPOTC ihapnaics b c\ l24C iwr Accepta DOC-I4M7 -0 23- Ct 12. A method for producing a parasite protein or fragment thereof in the milk of a non- human transgenic mammal, comprising: providing a non-human transgenic mammal whose genome comprises a modified nucleic acid sequence encoding said parasite protein or fragment thereof operably linked to a promoter which directs expression in a mammary gland, wherein the naturally occurring o nucleic acid sequence encoding said parasite protein or fragment thereof contains at least one n AUUUA mRNA instability motif; and wherein said modified nucleic acid sequence has been 0 modified by: replacing at least a portion of an AUUUA mRNA instability motif in the coding sequence of said parasite protein or fragment thereof as it naturally occurs in a parasite with a codon or codons preferred by a mammalian cell for the purposes of expression so as to remove said AUUUA mRNA instability motif or prevent said AUUUA mRNA instability motif from destabilising mRNAs encoding said parasite proteins or fragment thereof while encoding the same amino acid as the replaced portion of said AUUUA mRNA instability motif; replacing one or more AT-containing codons of said nucleic acid sequence as it naturally occurs in a parasite with a codon or codons preferred by a mammalian cell for the purposes of expression and encoding the same amino acid as the replaced codon; and allowing said non-human transgenic mammal to express said parasite protein or fragment thereof in its milk, to thereby produce said parasite protein or fragment thereof, wherein the AT content of the modified nucleic acid sequence is 50% or less and/or all said AUUUA mRNA instability motifs are eliminated, and wherein at least one glycosylation site on the parasite protein or fragment thereof has been altered. 13. The method of claim 12, wherein the at least one glycosylation site is at least one N-glycosylation site. 14. The method of any one of claims 12 or 13, wherein all of the glycosylation sites have been altered. COMS ID No: SBMI-05951604 Received by IP Australia: Time 12:10 Date 2007-01-17 17-01-'07 12:07 FROM- T-283 P007/023 F-047 P.AOERIPM\OTC BiotLaptMnios Ial314Cln(MIi ActtCpl..ce DOC-17Il0n1 24 ci The method of claim 12, wherein the parasite protein is a malarial protein. 16. The method of claim 12, wherein said modified nucleic acid sequence has at least one codon of the naturally occurring nucleic acid sequence of said parasite replaced with a O codon or codons preferred by a mammalian cell for the purposes of expression such that both 0, the AT content of said nucleic acid sequence of said parasite protein or fragment thereof is o lowered relative to that of said naturally occurring nucleic acid sequence of said parasite o protein or fragment thereof and the mRNA instability motif of said naturally occurring nucleic acid sequence of said parasite protein or fragment thereof is eliminated by the utilisation of an alternative codon or codons preferred by a mammalian cell for the purposes of expression. 17. The method of claim 12, wherein each of said AUUUA mRNA instability motifs present in the naturally occurring nucleic acid have been replaced by a codon or codons preferred by a mammalian cell for the purposes of expression so as to remove said AUUUA mRNA instability motif or prevent said AUUUA mRNA instability motif from destabilising mRNAs encoding said parasite protein or fragment thereof.

18. The method of claim 12, wherein said modified nucleic acid sequence further comprises at least one additional codon other than a first codon replaced to lower AT content or a nucleic acid sequence modification made to eliminate said AUUUA mRNA instability motif which has been replaced with a codon or codons preferred by a mammalian cell for the purposes of expression and encoding the same parasite protein or fragment thereof is found in the naturally occurring nucleic acid sequence.

19. The method of claim 12, wherein all of the codons of the naturally occurring nucleic acid sequence has been replaced with a codon or codons preferred by a mammalian cell for the purposes of expression and encoding the same parasite protein or fragment thereof as found in the naturally occurring nucleic acid sequence. COMS ID No: SBMI-05951604 Received by IP Australia: Time 12:10 Date 2007-01-17 17-01-'07 12:07 FROM- T-283 P008/023 F-047 P .OPERHPMGTC ItMonrauis Inrt3)240CClaiin rW Acclepumce DOC.L7011;T 0 S-

20. The method of any one of claims 12 to 19, wherein the or each codon preferred by a mammalian cell for the purposes of expression is a mammary tissue specific codon.

21. The method of any one of claims 12 to 20, wherein said parasite protein or fragment thereof is expressed in the milk of said non-human transgenic mammal at a level 0 of at least 0.5 mg/ml. 0 Cc o 22. The method of any one of claims 12 to 20, wherein said parasite protein or o fragment thereof is expressed in said non-human transgenic mammal at a level which is between 1.0 mg/mi and 2.0 mg/ml.

23. The method of any one of claims 12 to 20, wherein said parasite protein or fragment thereof as expressed in said non-human transgenic mammal can be detectably expressed in the milk of said transgenic non-human mammal.

24. The method of any one of claims 12 to 20, wherein all non-preferred colons are replaced with a codon or codons preferred by a mammalian cell for the purposes of expression. A non-human transgenic mammal whose germline comprises a modified nucleic acid sequence of any one of claims 1 to 7 operably linked to a promoter which directs expression in a mammary gland, wherein said non-human transgenic mammal expresses the parasite protein or fragment thereof encoded by said modified nucleic acid sequence in its milk.

26. A DNA vaccine comprising a modified nucleic acid sequence of any one of claims 1 to 7.

27. A DNA vaccine comprising a vector of claim 8. COMS ID No: SBMI-05951604 Received by IP Australia: Time 12:10 Date 2007-01-17 17-01-'07 12:08 FROM- T-283 P009/023 F-047 raPflftbi"M TC imsrwma ISI324CILms fr Apeuao.DOCI S- 26

28. A modified nucleic acid sequence according to any one of claims 1 to 7 or a vector according to claim 8 or a mammalian cell according to claim 9 or a transgenic expression construct according to any one of claims 10 to 11 or a method according to any one of claims 12 to 24 or a non-human transgenic mammal according to claim 25 or a DNA vaccine according to any one of claims 26 to 27 substantially as hereinbefore described C with reference to the Figures and Examples. 0 COMS ID No: SBMI-05951604 Received by IP Australia: Time 12:10 Date 2007-01-17